A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach.
|
| Abstract |
The Chinese medicine Qiliqiangxin (QL) has been shown to have a protective role in heart failure. Here, we explore the underlying working mechanism of the key therapeutic component in QL using a rat model of heart failure. Heart failure after myocardial infarction was induced surgically and confirmed using echocardiography; a separate group of rats underwent sham surgery. The rats with heart failure were randomly assigned to receive QL, the angiotensin-converting enzyme inhibitor benazepril, or placebo groups. Blood samples were collected from the rats at four time points for up to 8 weeks and used for biochemical analysis and mass spectrometry‒based metabolomics profiling. In total, we measured nine well-known biochemical parameters of heart failure and 147 metabolites. In the rats with heart failure, QL significantly improved these biochemical parameters and metabolomics profiles, significantly increasing the cardioprotective parameter angiopoietin-like 4 and significantly lowering inflammation-related oxylipins and lysophosphatidic acids compared to benazepril. Mechanistically, QL may improve outcome in heart failure by controlling inflammatory process and cardiac hypertrophy. Clinical studies should be designed in order to investigate these putative mechanisms in patients.
|
|---|---|
| Authors | Junzeng Fu, Liping Chang, Amy C Harms, Zhenhua Jia, Hongtao Wang, Cong Wei, Li Qiao, Shuyan Tian, Thomas Hankemeier, Yiling Wu, Mei Wang |
| Journal | Scientific reports (Sci Rep) Vol. 8 Issue 1 Pg. 3688 (02 27 2018) ISSN: 2045-2322 [Electronic] England |
| PMID | 29487344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!